

Year-end Report

January 1 - December 31, 2019



Year-end Report

January 1 – December 31, 2019

The fourth quarter in figures


- Net sales amounted to TSEK 5 069 (4 220).
- Loss after taxes amounted to TSEK 28 641 (15 755).
- Loss per share was SEK 1,6 (2,8).
- Cash flow from current operations was TSEK -24 023 (-26 887).

The full year in figures

- Net sales amounted to TSEK 16 873 (13 264).
- Loss after taxes amounted to TSEK 84 245 (56 011).
- Loss per share was SEK 5,5 (11,0).
- Cash flow from current operations was TSEK -71 616 (-66 018).

Important events during the fourth quarter

- UK National Health Service contract award received.
- First clinical experience with OssDsign implants on Japanese patients presented at the 78th Annual Meeting of the Japan Neurosurgical Society held in Osaka.
- The European Patent Office (EPO) granted OssDsign an additional European Patent related to the company's ceramic material technology.
- FDA clearance for OssDsign Cranial PSI Accessories received.
- Updated Post Market Surveillance data on the outcome



of 670 cranioplasties using OssDsign Cranial PSI are in line with OssDsign's previously published rate of complications - substantially lower than published data for traditional implants.

- Transition from master distributor to OssDsign USA Inc completed.

Important events after the end of the fourth quarter

- No important events have occurred after the end of the period.

Financial overview

<i>The group</i>	2019	2018	2019	2018
	Oct 1 - Dec 31	Oct 1 - Dec 31	Jan 1 - Dec 31	Jan 1 - Dec 31
Net sales, TSEK	5 069	4 220	16 873	13 264
Operating profit, TSEK	-28 641	-15 755	-83 526	-50 145
Profit for the period, TSEK	-28 867	-16 780	-84 245	-56 011
Solidity, %	88 %	63 %	88 %	63 %
Earnings per share, SEK	-1,6	-2,8	-5,5	-11,0
Average number of employees	38,8	29,7	35,5	27,3



“ Our strategy for, and investments in the US market generated the expected good results. ”

CEO Statement

Continued success in the US

OssDsign AB finished an exciting and eventful year on a very strong note. Our strategy for, and investments in the US market, as presented in the IPO process generated the expected good results.

Following the IPO in May, one of OssDsign's top priorities has been to transition from our US master distributor, Matador Medical to take full control of our US commercial operation via an OssDsign US subsidiary. This process is now complete and the commercial strategy based on a phased entry into the US has been demonstrated to be a success.

US sales orders accelerated during the second half of 2019 with consecutive quarterly growth, Q3 vs Q2 of 45%. Q4 was the first quarter with sales and order fulfilment managed directly through OssDsign USA Inc which coincided with very high order volume. If fulfilled in the quarter, the orders would have generated a growth rate of 57% Q4 vs Q3. However, as a result of logistical delays in the US over the holiday season some end-user deliveries were pushed from Q4 into the first few days of Q1 2020 resulting in a reported Q4 vs Q3 US growth of 32%.

During the fourth quarter OssDsign also received FDA clearance to market our cranial accessories in the US. This will further expand the patient population that will benefit from surgical treatment with our patient specific cranial implants.

Sales in Europe showed sustainable growth over the full year period despite a negative impact on Q4 sales due to year-end health care budget constraints in some markets. In France, where the search for a distribution partner is ongoing, several hospitals have, following national reimbursement approval, already ordered cranial implants. Overall, we remain confident that OssDsign's growth in Europe will be steady, strong and sustainable over the years to come. Early insights into the 2020 order book support this belief.

Preparations for the launch in Japan continued in the fourth quarter. More surgeries were performed under ethical approval giving additional Japanese surgeons experience prior to a regulatory approval and launch. Japanese neurosurgeons now have experience of using both OssDsign Cranial as well as CranioPlug, which will give important clinical support to the full commercial launch later this year.

Continued growth will be supported by the results of the recently updated Post Market Surveillance data which was collected for regulatory purposes and released publicly in November 2019. It reports the overall clinical outcome following 670 cranioplasty surgeries using OssDsign Cranial PSI with results confirming OssDsign's previously published low rates of complications, as well as being substantially lower than published data for traditional implants.

Undoubtedly 2019 has been a transformational year and I am sure 2020 will be as exciting as we are continuing to build a high-performing organization capable of leveraging the potential of our unique technology platform on a global scale.

Anders Lundqvist, CEO

Statement of Operations

OssDsign has developed a bioceramic material that, when implanted into a patient's body, is replaced by the patient's own bone during the healing process. Based on this bioceramic material, the company has developed patient-specific cranial and facial implants and an off-the-shelf product for burr hole filling.

Status

The company currently has regulatory approval in the EU and US and is successfully established in Europe. In the autumn of 2017, OssDsign initiated commercialization in the US, the world's largest medtech market. The company sees strong growth potential in the US and intends to carry out significant market initiatives there in the coming years. In addition, OssDsign will invest in continued growth in Europe and establishing a position in the Japanese market.

Objectives and Market Potential

Successful market initiatives have generated significant interest in the company's products, resulting in significant sales growth in recent years. OssDsign has determined that there is good potential to establish the company's patient-specific and off-the-shelf implants as the standard treatment for cranial and facial defects resulting from trauma, radiation therapy, tumor, stroke or congenital defects. During the second quarter of 2019 OssDsign was successfully listed as publically traded company. The IPO raised 139 MSEK of new capital after transaction costs, (for more information see note 4) providing OssDsign with the resources needed to establish the company as a fast-growing, profitable medtech company that creates value for customers while fulfilling our ambition to deliver meaningful benefit to patients.



Development of profit and financial position

FOURTH QUARTER

Net sales

Net sales for the fourth quarter amounted to TSEK 5 069 (4 220), an increase of 20%, which when cleared for currency effects shows that sales increased by 12%. The increase in sales was largely driven by a positive sales trend in the US (+96%), which delivered its strongest quarter since launch. Sales in Europe declined vs previous year by 14%, driven by year-end health care budget constraints in some markets.

Operating profit/loss

The operating loss for the period October - December 2019 amounted to TSEK -28 641 (-15 755), an increased loss of TSEK 12 886. The reduced operating profit is driven by increased investments mainly related to the sales organization in the USA and the production organization in Uppsala as part of manufacturing capacity scale up in order to meet increasing volumes. The operating loss is also impacted by a reduction in the capitalisation of own work.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents amounted to TSEK 137 467 and, at the end of the period, were TSEK 113 540. Cash flow from current operations for the period was negative by TSEK 24 023 (-26 887) of which changes in working capital amounted to TSEK 4 124 (-10 825). The negative operating cash flow was mainly a result of increased investment in the marketing, sales and production organizations. Financing activities including payment of premiums for warrants contributed TSEK 120 (+31 136). Total cash flow for the period was negative to the amount of TSEK 23 941 (1 793). Net investments in tangible assets for the period amounted to TSEK 38 (179) and mainly related to investments linked to the establishment of a US office. Investments in intangible assets for the period amounted to TSEK 0 (2 277).

FULL YEAR

Net sales

Net sales for the full year of 2019 amounted to TSEK 16 873 (13 264), an increase of 27%, cleared for currency effects sales increased by 20%. The increase in sales was largely driven by a positive sales trend in the USA (+53%). The more established markets in Europe also contributed to the strong sales performance, with the UK as the biggest contributing factor (+51%).

Operating profit/loss

The operating loss for the full year of 2019 amounted to TSEK -83 526 (-50 145), an increased loss of TSEK 33 381. The reduced operating profit is driven by increased investments mainly related to the sales organization in the USA and the production organization in Uppsala. Operating loss is also impacted by costs linked to the listing on Nasdaq First North and the reduction of the capitalisation of own work.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents amounted to TSEK 14 077 and, at the end of the period, were TSEK 113 540. Cash flow from current operations for the period was negative by TSEK 71 616 (-66 018) of which changes in working capital amounted to TSEK 10 069 (-11 934). The negative operating cash flow deteriorated mainly as a result of an increased loss driven by the increased investment in the market and production organization. Financing activities including the listing on First North in Q2 contributed a positive 171 337 TSEK (52 552). Total cash flow for the period was positive to the amount of TSEK 99 396 (-21 123). Net investments in tangible assets for the period amounted to TSEK 231 (960) and mainly related to investments in production as part of manufacturing capacity scale up in order to meet increasing volumes as well as office equipment. Investments in intangible assets for the period amounted to TSEK 95 (6 696).

IMPORTANT EVENTS DURING THE QUARTER

UK National Health Service (NHS) contract award received

In October OssDsign received the final award contract from UK National Health Service (NHS) for the National Framework Agreement "Total Orthopaedic Solutions 2". Being awarded this contract means that all OssDsign's current products will be covered under a single National Framework Agreement open to all NHS hospitals the UK. The contract to be valid from February 3rd, 2020 for a period of four years.

First clinical experience with OssDsign Cranial implants on Japanese patients presented at the 78th Annual Meeting of the Japan Neurosurgical Society held in Osaka

The first clinical experience with OssDsign Cranial PSI implants in Japanese patients was recently presented by the highly respected Prof. Takuji Yamamoto at the 78th Annual Meeting of the Japan Neurosurgical Society held in Osaka in October and further surgeries on additional patients were performed by Prof. Yamamoto during the fourth quarter. The clinical experience from these patients will form an important base for the introduction of OssDsign Cranial in Japan once the regulatory approval has been received.

The European Patent Office (EPO) granted OssDsign an additional European Patent related to the company's ceramic material technology

In October, the European Patent Office (EPO) granted OssDsign a new European Patent related to the Company's ceramic material technology. The Patent provides further protection of the technology related to the unique biological properties of the OssDsign implants. The Patent covers the European market and is valid to 2033. Previously Patents of the same family have been granted in other key markets including USA and Japan.

FDA clearance for OssDsign Cranial PSI Accessories received

In October, the US Food and Drug Administration (FDA) granted 510(k) clearance to market (K190523) for OssDsign Cranial PSI Accessories in the US. The cleared products are a set of 3D-printed, patient specific accessory devices designed to support and expand clinical use of OssDsign's patient specific cranioplasty implant already cleared by the FDA. The accessories are designed to make cranial reconstructions safer and easier and to enable new solutions for patients in need of complex cranial reconstructions. The FDA clearance will enable OssDsign to continue to drive growth in the US by gaining access to additional cohorts of patients with complex cranial defects and by further differentiating the OssDsign product.

Updated Post Market Surveillance data on the outcome of 670 cranioplasties using OssDsign Cranial PSI are in line with OssDsign's previously published rate of complications - substantially lower than published data for traditional implants.


As part of continuous post-market surveillance following introduction of OssDsign Cranial PSI, an updated report has been compiled describing the outcome of 670 cranioplasties using OssDsign Cranial PSI. The data, collected in Europe, US and selected Asian markets, shows 2,4% of patients experiencing infections requiring re-operation compared to 7-12% reported for traditional implants. This data continues to be in line with previously published data on the low rate of complications with OssDsign Cranial PSI.

Transition from master distributor to OssDsign USA Inc completed

The process to transition US commercial operations from our master distributor, Matador Medical to OssDsign USA Inc was completed during the fourth quarter. The process, carefully staged in collaboration with Matador Medical, means that all hospital contracts have been transferred to OssDsign USA Inc, giving us full control of the commercial operations, while optimizing the distributor network established during the collaboration with Matador Medical.

IMPORTANT EVENTS AFTER THE END OF THE PERIOD

No important events after the end of the fourth quarter.



OTHER DISCLOSURES

Ownership structure

At the end of the third quarter there were approximately 1 396 shareholders in OssDsign AB, of which the three largest accounted for 39,9% of the capital and voting rights. The total number of shares amounted to 17 733 168. The largest shareholders as of Dec 31, 2019, were SEB Ventures, Karolinska Development AB, and Fourier Transform AB.

Group structure

OssDsign AB is the parent company of the Group, which in addition to OssDsign AB consists of the wholly owned subsidiaries OssDsign Ltd with its registered office in UK and OssDsign USA Inc with its registered office in Delaware, USA. OssDsign's operations are mainly conducted through the parent company OssDsign AB, based in Uppsala. During the third quarter, an operating office for OssDsign USA Inc was opened in Columbia, Maryland, which will become the center of US operations.

Employees

At the close of the period, there were a total of 40 (29) employees, of whom 43% were women. This includes employees at the office and production plant in Uppsala, as well as sales representatives in Germany, the UK and USA.

Financing

The board of directors regularly reviews the Company's current and forecast cash flows to ensure it has the necessary funds


and resources to conduct operations and work in the strategic direction agreed by the board. The Company's long-term cash requirement is largely determined by how successful current products are, or are anticipated to be, in the market. In May 2019, in connection with the Company's listing on the Nasdaq First North exchange, a new rights issue was carried out, realising 151,3 MSEK before deduction of issue costs. The net amount raised was approximately 139,6 MSEK. The board deems that the current cash position is sufficient to implement the Company's current business plan.

Transactions with related parties

On the balance sheet date, there were no receivables from or liabilities attributable to related parties. There have been no transactions between the Company and related parties that have had a material impact on the Company's position and results.

Risks and uncertainties

OssDsign risks and uncertainties include, but are not limited to, financial risks such as future financing, foreign exchange and credit risks. In addition to market risks, there are risks related to OssDsign operations, such as obtaining the necessary government licenses, product development, patents and intellectual property rights, product liability and forward-looking information that may affect the Company. Further information regarding the Company's risk exposure can be found on page 35-36 of OssDsign 2018 Annual report.



Consolidated summary income statement

<i>SEK 000'</i>	2019	2018	2019	2018
	Oct 1 – Dec 31	Oct 1 – Dec 31	Jan 1 – Dec 31	Jan 1 – Dec 31
Net sales	5 069	4 220	16 873	13 264
Other operating income/Other income	329	445	1 723	2 373
Work performed by the group/parent company for its own use and capitalised	0	2 277	95	6 696
Raw materials and consumables/Cost of material	-2 492	-1 494	-7 205	-4 947
Other external expenses	-16 610	-10 755	-44 844	-33 048
Personnel costs	-13 416	-9 416	-44 901	-30 290
Depreciation, amortisation and impairment of tangible and intangible fixed assets/ non-financial assets	-1 035	-935	-4 099	-3 628
Impairment losses on financial assets	-38	-54	-176	-152
Other operating expenses/Other expenses	-447	-41	-992	-412
Operating profit	-28 641	-15 755	-83 526	-50 145
<i>Profit from financial items</i>				
Net interest income	-48	-1 019	-226	-5 716
Profit after financial items	-28 689	-16 774	-83 752	-55 861
Tax expense	-178	-6	-493	-150
Profit for the period	-28 867	-16 780	-84 245	-56 011
Earnings per share				
Basic earnings per share, SEK	-1,6	-2,8	-5,5	-11,0

Consolidated summary of comprehensive income

<i>SEK 000'</i>	2019	2018	2019	2018
	Oct 1 – Dec 31	Oct 1 – Dec 31	Jan 1 – Dec 31	Jan 1 – Dec 31
Profit/loss for the period	-28 867	-16 780	-84 245	-56 011
<i>Other comprehensive income for the period</i>				
Items that will be reclassified subsequently to profit or loss	-2	-4	18	19
Income tax relating to items that will be reclassified	0	0	0	0
Other comprehensive income for the period	-2	-4	18	19
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	-28 868	-16 784	-84 228	-55 992

Consolidated summary balance sheet

<i>SEK 000'</i>	2019	2018
	Dec 31	Dec 31
ASSETS		
<i>Fixed assets</i>		
Intangible fixed assets	26 431	28 514
Tangible fixed assets	3 608	8 108
Total fixed assets	30 040	36 623
<i>Current assets</i>		
Inventories	1 752	1 354
Current receivables	5 266	6 100
Other receivables	1 650	16 319
Prepaid expenses and other accrued income	1 020	649
Cash equivalents	113 540	14 077
Total current assets	123 227	38 498
TOTAL ASSETS	153 267	75 120

<i>SEK 000'</i>	2019	2018
	Dec 31	Dec 31
SHAREHOLDER EQUITY AND LIABILITIES		
Equity	135 275	47 492
Total equity	135 275	47 492
<i>Long-term liabilities</i>		
Liabilities to credit institutions	2 310	2 781
Lease liabilities	976	4 287
Other liabilities	0	113
Total long-term liabilities	3 286	7 181
<i>Current liabilities</i>		
Liabilities to credit institutions	513	627
Accounts payable	2 911	4 044
Lease liabilities	750	1 745
Current tax liabilities	356	548
Other liabilities	1 868	5 957
Accrued expenses and deferred income	8 308	7 528
Total current liabilities	14 706	20 448
Total liabilities	17 992	27 628
TOTAL EQUITY AND LIABILITIES	153 267	75 120

Consolidated change in shareholder's equity in summary

<i>SEK 000'</i>	Share capital	Subscribed Capital Unpaid	Other Capital Contributions	Reserves	Profit (loss) brought forward	Total Equity
Opening balance 2018-01-01	299	-	70 200	-2	-20 078	50 419
Profit/loss for the period	-	-	-	-	-56 011	-56 011
Other comprehensive income	-	-	-	19	-	19
Total comprehensive income	-	-	-	19	-56 011	-55 992
<i>Transactions with shareholders</i>						
Redeemed convertibles	-	-	-70 200	-	-	-70 200
Rights issue	49	330	124 477	-	-	124 857
Issue expenses	-	-	-1 591	-	-	-1 591
Total transactions with shareholders	49	330	52 686	-	-	53 065
CLOSING BALANCE 2018-12-31	49	330	122 886	17	-76 090	47 492
Opening balance 2019-01-01	348	330	122 886	17	-76 090	47 492
Profit/loss for the period	-	-	-	-	-84 245	-84 245
Other comprehensive income	-	-	-	1	17	18
Total comprehensive income	-	-	-	1	-84 228	-84 228
<i>Transactions with shareholders</i>						
New share issue	760	-330	183 416	-	-	183 846
Issue expenses	-	-	-13 315	-	-	-13 315
Warrant programmes	-	-	1 479	-	-	1 479
Total transactions with shareholders	760	-330	171 581	-	-	172 010
CLOSING BALANCE 2019-12-31	1 108	-	294 467	18	-160 318	135 275

Consolidated summary statement of cash flows

	2019	2018	2019	2018
SEK 000'	Oct 1 – Dec 31	Oct 1 – Dec 31	Jan 1 – Dec 31	Jan 1 – Dec 31
Operating activities				
Profit after financial items	-28 689	-16 774	-83 752	-55 861
Non cash adjustments	670	791	2 752	2 435
Income tax paid	-128	-79	-685	-658
	-28 147	-16 062	-81 685	-54 084
Change in inventory	-532	-438	-411	-872
Change in receivables	-1 150	-18 033	14 957	-19 997
Change in liabilities	3 506	7 645	-4 476	8 935
Total change in working capital	4 124	-10 825	10 069	-11 934
Cash flow from operating activities	-24 023	-26 887	-71 616	-66 018
Investment activities				
Acquisition of intangible fixed assets	0	-2 277	-95	-6 696
Acquisition of tangible fixed assets	-38	-179	-231	-960
Cash flow from investment activities	-38	-2 456	-326	-7 656
Financing activities				
New share issue	0	8 286	170 531	30 186
New borrowing	0	22 682	0	22 879
Warrants	234	0	1 390	0
Repayment of borrowing	-114	167	-584	-513
Cash flow from financing activities	120	31 136	171 337	52 552
Cash flow for the period	-23 941	1 793	99 396	-21 123
Cash equivalents at the beginning of the period	137 467	12 351	14 077	35 233
Exchange rate differences in cash equivalents	14	-67	68	-34
CASH EQUIVALENTS AT THE END OF THE PERIOD	113 540	14 077	113 540	14 077

Summary income statement, parent company

SEK 000'	2019	2018	2019	2018
	Oct 1 – Dec 31	Oct 1 – Dec 31	Jan 1 – Dec 31	Jan 1 – Dec 31
Net sales	5 530	4 220	17 333	13 264
Other operating income/Other income	329	445	1 723	2 373
Raw materials and consumables/Cost of material	-2 697	-1 495	-7 210	-4 947
Other external expenses	-22 744	-13 752	-62 465	-41 952
Personnel costs	-8 026	-7 090	-30 613	-23 839
Depreciation, amortisation and impairment of tangible and intangible fixed assets/ non-financial assets	-165	-151	-657	-555
Other operating expenses	-447	-41	-992	-412
Operating profit	-28 220	-17 865	-82 880	-56 069
<i>Profit from financial items</i>				
Net interest income	-31	-966	-146	-5 494
Profit after financial items	-28 251	-18 831	-83 026	-61 563
Tax expense	-	-	-	-
PROFIT FOR THE PERIOD	-28 251	-18 813	-83 026	-61 563

*Other comprehensive income in the Parent Company is in line with the profit for the period.

Summary balance sheet, parent company

	2019	2018
<i>SEK 000'</i>	Dec 31	Dec 31
ASSETS		
Subscribed capital unpaid	-	15 211
Fixed assets		
Tangible fixed assets	1 811	2 414
Financial assets		
Shares in group companies	0	0
Total financial fixed assets	0	0
Total fixed assets	1 811	2 414
Current assets		
Inventories	1 479	1 354
Current receivables	3 729	5 531
Receivables from group companies	648	972
Other receivables	1 586	1 103
Prepaid expenses and other accrued income	1 062	813
Cash equivalents	112 091	12 647
Total current assets	120 595	22 419
TOTAL ASSETS	122 406	40 044

	2019	2018
<i>SEK 000'</i>	Dec 31	Dec 31
SHAREHOLDER EQUITY AND LIABILITIES		
Equity		
Restricted equity	1 108	678
Non-restricted equity	106 857	18 303
Total equity	107 965	18 981
Long-term liabilities		
Liabilities to credit institutions	2 310	2 781
Other liabilities	0	113
Total long-term liabilities	2 310	2 894
Current liabilities		
Liabilities to credit institutions	513	513
Accounts payable	2 604	4 004
Liabilities to group companies	445	0
Current tax liabilities	356	548
Other current liabilities	949	5 794
Accrued expenses and deferred income	7 263	7 310
Total current liabilities	12 130	18 169
Total liabilities	14 440	21 062
TOTAL EQUITY AND LIABILITIES	122 406	40 044

Notes

Note 1 | Accounting principles

This summary interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable regulations in the Swedish Annual Accounts Act. The interim report for the Parent company has been prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim Financial Reporting. The same accounting and valuation policies have been applied for the Group and the parent Company as in the latest Annual report. Disclosures in accordance with IAS 34.16A occur in the financial reports and the accompanying notes, and also in other parts of the interim report.

Note 2 | Estimates and assessments

Estimates and assessments are evaluated on an ongoing basis and are based on historical experience and other factors, including expectations of future events that are considered reasonable under prevailing conditions. There has been no change in the estimates and judgments made in the annual report for 2018.

Note 3 | Information regarding operating segments

The Group's operations are divided into operating segments based on the parts of the business the Company's highest executive decision-maker follows up, so called "management approach". The Group's internal reporting is based on the Group management following up the operation as a whole. Based on its internal reporting, the Group has identified that the Group has only one segment.

NET SALES BY GEOGRAPHIC MARKET

SEK 000'	October - December		January - December	
	2019	2018	2019	2018
USA	2 490	1 272	6 832	4 459
Europe	2 494	2 887	9 849	8 523
Rest of World	85	61	192	282
TOTAL	5 069	4 220	16 873	13 263

Income from external customers has been attributed to individual countries from which the sales has taken place. The Group's fixed assets are located entirely in Sweden.

OssDsign has revenue from an individual customer (master distributor Matador Medical Inc) amounting to >10%. Total revenue from this customer during Q4-2019 amounts to TSEK 574 (1 272) and for the full year of 2019 to TSEK 4 703 (4 459).

Note 4 | Equity

The share capital of the Parent Company consists only of fully paid ordinary shares with a nominal (quota value) value of SEK 0.0625 / share. The company has 17 733 168 class A shares.

	2019	2018
	Jan 1 - Dec 31	Jan 1 - Dec 31
Subscribed and paid shares:		
At the beginning of the period	348 007	299 175
Registration of new share issue decided 2018	330 333	
Rights issue	5 586 233	48 832
Division of shares 16:1	11 468 595	
Subscribed and paid shares	17 733 168	299 175
Shares for share-based payments	-	-
SUM AT THE END OF THE PERIOD	17 733 168	299 175

During the first quarter the Company registered 330 333 shares which were issued and decided upon in 2018. Additionally, the Company issued during the first quarter 2019 a new share issue which increased the number of shares by an additional 86 233. Further, the Company has divided the shares into a ratio of 16:1.

The company completed a new share issue during the second quarter, which increased the number of shares by 5 500 000. The total number of shares subsequently amounted to 17 733 168 and with a quota value 0.0625. The Group's issued shares have the same right to distribute and repay invested capital and represent a vote at OssDsign's Annual General Meeting.

Resolved shares that have not yet been issued have been approved solely for use in the Group's options program (for more information see note 7 in the Annual Report 2018). Amounts received for issued shares in addition to the nominal value during the year (premium) are included in the item "Other contributed capital", after deduction for registration and other similar fees and after deduction for attributable tax benefits.

During the year, the company implemented new issues and options programs totaling SEK 171 580 509 after issue costs.

Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earning of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

This report has been prepared in both a Swedish and an English version. In the event of any discrepancy between the two, the Swedish version shall apply. This report has not been audited.

OSSDSIGN AB – UPPSALA 13 FEBRUARY 2020

Simon Cartmell
Chairman of the Board

Viktor Drvota
Board member

Håkan Engqvist
Board member

Newton Aguiar
Board member

Anders Qvarnström
Board member

Anders Lundqvist
CEO

SCHEDULED FINANCIAL REPORTS

Annual Report 2019

March 26, 2020

Interim Report, first quarter 2020

May 13, 2020

Interim Report, third quarter 2020

November 11, 2020

AGM

April 16, 2020

Interim Report, second quarter 2020

August 19, 2020



ADDRESS

OssDsign AB
Virdings Allé 2
754 50 Uppsala
Sweden

+46(0)18-55 39 93
Org.nr: 556841-7546

CONTACT

Anders Lundqvist, CEO
+46(0)73-206 98 08
al@ossdsign.com

Claes Lindblad, CFO
+46(0)70-865 36 87
c.lindblad@ossdsign.com

OSSDSIGN[®]

OssDsign AB, Virdings Allé 2, SE 754 50 Uppsala, Sweden

+46(0)18-55 39 93

info@ossdsign.com

ossdsign.com

